The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Cardiovascular Safety-MedSci.cn

The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Cardiovascular Safety

Lipson, DA; Criner, G; Dransfield, MT; Halpin, DMG; Han, MK; Jones, CE; Kilbride, S; Lange, P; Lomas, DA; Martinez, FJ; Pascoe, S; Singh, D; Wise, RA

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019; 199 ():

科室
- - 订阅+
  - 更多科室
工具
服务